From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.
The company we are referring to is Monopar Therapeutics Inc. (MNPR), developing ALXN1840 for Wilson Disease and MNPR-101 as a novel radiopharmaceutical targeting uPAR (urokinase-type plasminogen activator receptor), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.